BMC Health Services Research (Nov 2022)

Similar costs and outcomes for differentiated service delivery models for HIV treatment in Uganda

  • Teresa Guthrie,
  • Charlotte Muheki,
  • Sydney Rosen,
  • Shiba Kanoowe,
  • Stephen Lagony,
  • Ross Greener,
  • Jacqueline Miot,
  • Hudson Balidawa,
  • Josen Kiggundu,
  • Jacqueline Calnan,
  • Seyoum Dejene,
  • Thembi Xulu,
  • Ntombi Sigwebela,
  • Lawrence C Long

DOI
https://doi.org/10.1186/s12913-022-08629-4
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 10

Abstract

Read online

Abstract This cost-outcome study estimated, from the perspective of the service provider, the total annual cost per client on antiretroviral therapy (ART) and total annual cost per client virally suppressed (defined as 18 years old) enrolled in a DSDM. The study found that retention in care was 98% for the sample as a whole [96–100%], and viral suppression, 91% [86-93%]. The mean cost to the provider (MOH or NGO implementers) was $152 per annum per client treated, ranging from $141 to $166. Differences among the models’ costs were largely due to clients’ ARV regimens and the proportions of clients on second line regimens. Service delivery costs, excluding ARVs, other medicines and laboratory tests, were modest, ranging from $9.66–16.43 per client per year. We conclude that differentiated ART service delivery in Uganda achieved excellent treatment outcomes at a cost similar to the standard of care. While large budgetary savings might not be immediately realized, the reallocation of “saved” staff time could improve health system efficiency and with their equivalent or better outcomes and large benefits to clients, client-centred differentiated models would nevertheless add great societal value.

Keywords